Milnacipran: Beyond a role of antidepressant

Chi Un Pae, David M. Marks, Manan Shah, Changsu Han, Byung Joo Ham, Ashwin A. Patkar, Prakash S. Masand

    Research output: Contribution to journalReview articlepeer-review

    37 Citations (Scopus)

    Abstract

    Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) with negligible effects on any presynaptic or postsynaptic receptors. Milnacipran has unique pharmacokinetic and pharmacodynamic characteristics that distinguish it from the other marketed serotonin and norepinephrine reuptake inhibitors, venlafaxine, desvenlafaxine, and duloxetine such as equipotent serotonin and norepinephrine reuptake inhibition and a linear dose-concentration trend at therapeutic doses. The half-life of milnacipran is approximately 8 hours. In addition, milnacipran does not inhibit the cytochrome P 450 system, indicating minimal propensity for drug-drug interactions. The antidepressant efficacy of milnacipran has been clearly established in a number of randomized, double-blind, placebo-controlled clinical trials, and it has been widely used for treating major depressive disorder. Moreover, evidence suggests that milnacipran is effective and tolerable in the treatment of fibromyalgia and may have usefulness for fatigue and anxiety symptoms. The current paper reviews researches conducted to date that is relevant to the efficacy, tolerability, and mechanism of action of milnacipran in the treatment of depression, fibromyalgia, and other psychiatric syndromes. Future directions of research are also identified.

    Original languageEnglish
    Pages (from-to)355-363
    Number of pages9
    JournalClinical Neuropharmacology
    Volume32
    Issue number6
    DOIs
    Publication statusPublished - 2009 Nov

    Keywords

    • Antidepressant
    • Anxiety
    • Fatigue
    • Fibromyalgia
    • Milnacipran
    • Pain

    ASJC Scopus subject areas

    • Pharmacology
    • Clinical Neurology
    • Pharmacology (medical)

    Fingerprint

    Dive into the research topics of 'Milnacipran: Beyond a role of antidepressant'. Together they form a unique fingerprint.

    Cite this